Congestive heart failure Sodium-glucose co-transporter 2 inhibitors

Jump to navigation Jump to search

Overview

Sodium-glucose co-transporter 2 (SGLT2) inhibitors (dapagliflozin or empagliflozin) are recommended for patients with HFrEF regardless of the presence or absence of diabetes, in addition to optimal medical therapy with an ACE-I/ARNI, a beta-blocker, and an aldosterone antagonist.

Sodium-glucose co-transporter 2 inhibitors

Indications for Sodium-glucose co-transporter 2 inhibitors

A patient should be on a Sodium-glucose co-transporter 2 inhibitor if: 1. The left ventricular ejection fraction (LVEF) is ≤ 40%


AND

2. The patient is already taking an ACE-I/ARNI, a beta-blocker, and an aldosterone antagonist.

  • SGLT2 inhibitors should be administered for all patients with HFrEF regardless of diabetes status.

Background

Dosing

Contraindications